Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.19−1.16 (-10.22%)
Close on Nov 12, 2026Market cap $655.77MP/E –Yield –
Cullinan Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Cullinan Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $169.67M, down 8.3% year over year. For fiscal 2025 it was $187.40M, up 31.1% from the year before. The highest annual figure on record is $187.40M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.40M | +31.1% |
| FY2024 | Dec 31, 2024 | $142.90M | -3.5% |
| FY2023 | Dec 31, 2023 | $148.16M | +61.1% |
| FY2022 | Dec 31, 2022 | $91.95M | +59.2% |
| FY2021 | Dec 31, 2021 | $57.75M | +33.6% |
| FY2020 | Dec 31, 2020 | $43.21M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $40.17M | -4.3% |
| Q2 FY2026 | Jun 30, 2026 | $44.44M | -27.2% |
| Q1 FY2026 | Mar 31, 2026 | $42.12M | +1.6% |
| Q4 FY2025 | Dec 31, 2025 | $42.95M | +6.1% |
| Q3 FY2025 | Sep 30, 2025 | $41.97M | +18.2% |
| Q2 FY2025 | Jun 30, 2025 | $61.03M | +68.3% |
| Q1 FY2025 | Mar 31, 2025 | $41.46M | +35.3% |
| Q4 FY2024 | Dec 31, 2024 | $40.49M | +16.2% |
| Q3 FY2024 | Sep 30, 2024 | $35.51M | +5.0% |
| Q2 FY2024 | Jun 30, 2024 | $36.26M | +32.4% |
| Q1 FY2024 | Mar 31, 2024 | $30.65M | -41.2% |
| Q4 FY2023 | Dec 31, 2023 | $34.85M | +63.4% |
| Q3 FY2023 | Sep 30, 2023 | $33.82M | +71.9% |
| Q2 FY2023 | Jun 30, 2023 | $27.39M | +3.7% |
| Q1 FY2023 | Mar 31, 2023 | $52.10M | +112.3% |
| Q4 FY2022 | Dec 31, 2022 | $21.32M | +2.1% |
| Q3 FY2022 | Sep 30, 2022 | $19.68M | +55.2% |
| Q2 FY2022 | Jun 30, 2022 | $26.41M | +124.2% |
| Q1 FY2022 | Mar 31, 2022 | $24.54M | +97.6% |
| Q4 FY2021 | Dec 31, 2021 | $20.88M | +25.6% |
| Q3 FY2021 | Sep 30, 2021 | $12.68M | +27.9% |
| Q2 FY2021 | Jun 30, 2021 | $11.78M | -5.7% |
| Q1 FY2021 | Mar 31, 2021 | $12.42M | +197.5% |
| Q4 FY2020 | Dec 31, 2020 | $16.63M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.91M | – |
| Q2 FY2020 | Jun 30, 2020 | $12.50M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.17M | – |
See a number that looks wrong?